Clinical Trials

Multiple clinical trials evaluate benztropine mesylate across diverse indications, including psychiatric conditions (schizophrenia, schizoaffective disorder, and psychotic disorders), pain states (chronic back pain, sciatica, and temporomandibular joint disorders), HIV-associated peripheral neuropathy, functional somatic disorders, and cocaine use disorders. Sponsored by prominent academic and governmental institutions such as the National Institute of Mental Health and the US Department of Veterans Affairs, these Phase 2, Phase 4, and non-applicable phase protocols currently hold completed, recruiting, or terminated recruitment statuses.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06232473 RECRUITING
Functional Disorder
Aarhus University Hospital
 2024-01-01 PHASE4
NCT00964886 COMPLETED
Back Pain
VA Office of Research and Development
 2010-01 PHASE2
NCT00715377 TERMINATED
Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder; Delusional Disorder; Psychotic Disorders
Centre for Addiction and Mental Health
 2007-06
NCT00802100 COMPLETED
Schizophrenia
National Institute of Mental Health (NIMH)
 2008-12 PHASE4
NCT00066937 COMPLETED
Temporomandibular Joint Disorders
Johns Hopkins University
 2002-11 PHASE2
NCT00715377 Terminated
Schizophrenia|Schizoaffective Disorder|Schizophreniform Disorder|Delusional Disorder|Psychotic Disorders
Centre for Addiction and Mental Health
 2007-06 Not Applicable
NCT00018200 COMPLETED
Back Pain; Sciatica
US Department of Veterans Affairs
 1999-04 PHASE2
NCT00000333 COMPLETED
Cocaine-Related Disorders
National Institute on Drug Abuse (NIDA)
 2001-05 PHASE2
NCT00000793 COMPLETED
HIV Infections; Peripheral Nervous System Disease
National Institute of Allergy and Infectious Diseases (NIAID)
 PHASE2

(data from https://clinicaltrials.gov, updated on 2024-01-30)

Check the Benztropine mesylate product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Benztropine mesylate binds to and inhibits the dopamine transporter with an IC50 of 118 nM, blocking the presynaptic reuptake of dopamine and increasing neurotransmitter availability within the synaptic cleft. This modulation of central dopaminergic and cholinergic pathways helps mitigate motor impairment and extrapyramidal symptoms in patients evaluated for psychotic disorders such as schizophrenia.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.